Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Fas Ligand (TNF Superfamily, Member 6) (FASL) antibody
|7 references available|
|Quantity||100ug (Not applicable.)|
|Price||641.67 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 4 to 5 Business Days|
|Alternative name||Fas L|
|Immunogen||Recombinant human Fas ligand.|
|Description||MAb to Fas L Monoclonal Antibody to Fas L|
|Specificity||Apoptosis or programmed-cell death is a physiological process essential for the normal development and maintenance or homeostasis in many organisms. This ?cellular suicide? can be triggered by the interaction of two cell-surface molecules, the Fas antigen (CD95) and its ligand, the Fas ligand or FasL.(1) The FasL is a type II membrane protein of M, 40kDa and is a member of the tumor necrosis factor (TNF) family.(2,3) It is expressed by activated T cells.(4) A 26kDa soluble form of human FasL (sFasL) exists and has been detected in the supernatant of human peripheral NK cells (5) and lymphocytes (6) upon activation. Reacts with human FasL specifically.(5) Cross-reactivity with other species has not been tested yet.|
|Synonyms||FASL, CD178, CD95L, TNFSF6, APT1LG1, gld, Fas-L, Faslg, Tnfsf6, Fas-Ligand, FASLG, fasl, APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6, lpr, APO1, TNFR6, Tnfrsf6, AI196731, Fasl, CD95-L, Apt1Lg1, FAS, LOC574159, zgc:162027|
|Application Notes||Flow cytometry: Recommended: 10ug/ml as a final concentration ELISA Neutralization of soluble Fas ligand cytotoxic-activity.(5) Not suitable for immunoblotting. Each laboratory should determine an optimum working titer for use in its particular application.|
|Buffer||Lyophilized from PBS containing 1% sucrose.|
|Storage||Store lyophilized product at 2-8°C. After reconstitution, aliquot and store for up to 3 months at -20°C. Avoid multiple freeze/thaw cycles.Reconstitute with 100ul of distilled water.|
|Restrictions||For Research Use only|
Suda, Takahashi, Golstein et al.: "Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family." in: Cell, Vol. 75, Issue 6, pp. 1169-78, 1994 (PubMed).
Alderson, Tough, Davis-Smith et al.: "Fas ligand mediates activation-induced cell death in human T lymphocytes." in: The Journal of experimental medicine, Vol. 181, Issue 1, pp. 71-7, 1995 (PubMed).
Nagata, Golstein: "The Fas death factor." in: Science (New York, N.Y.), Vol. 267, Issue 5203, pp. 1449-56, 1995 (PubMed).
Tanaka, Suda, Takahashi et al.: "Expression of the functional soluble form of human fas ligand in activated lymphocytes." in: The EMBO journal, Vol. 14, Issue 6, pp. 1129-35, 1995 (PubMed).
Takahashi, Tanaka, Inazawa et al.: "Human Fas ligand: gene structure, chromosomal location and species specificity." in: International immunology, Vol. 6, Issue 10, pp. 1567-74, 1995 (PubMed).
Tanaka, Suda, Haze et al.: "Fas ligand in human serum." in: Nature medicine, Vol. 2, Issue 3, pp. 317-22, 1996 (PubMed).
Sato, Kimura, Nakamura et al.: "An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand." in: British journal of haematology, Vol. 94, Issue 2, pp. 379-82, 1996 (PubMed).